newsfilter
← Latest News
Business Wire·

AlloVir Reports Second Quarter 2022 Financial Results

Three Phase 3 Posoleucel Registrational Trials Continue to Expand Globally, Enrolling Patients in the U.S., Europe and Asia Company Is On Track to Release Final Results of Posoleucel Phase 2 Multi-Virus Prevention Study at Year-End and Topline Result